These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19369444)

  • 1. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.
    Musta AC; Riederer K; Shemes S; Chase P; Jose J; Johnson LB; Khatib R
    J Clin Microbiol; 2009 Jun; 47(6):1640-4. PubMed ID: 19369444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.
    Sancak B; Yagci S; Gür D; Gülay Z; Ogunc D; Söyletir G; Yalcin AN; Dündar DO; Topçu AW; Aksit F; Usluer G; Ozakin C; Akalin H; Hayran M; Korten V
    BMC Infect Dis; 2013 Dec; 13():583. PubMed ID: 24325260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.
    Pitz AM; Yu F; Hermsen ED; Rupp ME; Fey PD; Olsen KM
    J Clin Microbiol; 2011 Jan; 49(1):269-74. PubMed ID: 20962147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.
    Takata T; Miyazaki M; Futo M; Hara S; Shiotsuka S; Kamimura H; Yoshimura H; Matsunaga A; Nishida T; Ishikura H; Ishikawa T; Tamura K; Tsuji BT
    Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
    Ozmen Capin BB; Tekeli A; Karahan ZC
    Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
    [No Abstract]   [Full Text] [Related]  

  • 11. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration.
    Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chen WJ; Chang SC; Hsueh PR
    Clin Infect Dis; 2012 Nov; 55(10):1329-37. PubMed ID: 22911641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
    da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR
    PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method.
    Wang JL; Wang JT; Sheng WH; Chen YC; Chang SC
    BMC Infect Dis; 2010 Jun; 10():159. PubMed ID: 20529302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
    Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
    BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.
    Park KH; Kim ES; Kim HS; Park SJ; Bang KM; Park HJ; Park SY; Moon SM; Chong YP; Kim SH; Lee SO; Choi SH; Jeong JY; Kim MN; Woo JH; Kim YS
    J Antimicrob Chemother; 2012 Aug; 67(8):1843-9. PubMed ID: 22535621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of heterogeneous vancomycin-intermediate
    Amberpet R; Sistla S; Sugumar M; Nagasundaram N; Manoharan M; Parija SC
    Indian J Med Res; 2019 Aug; 150(2):194-198. PubMed ID: 31670275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.
    Mendes RE; Sader HS; Deshpande LM; Diep BA; Chambers HF; Jones RN
    J Clin Microbiol; 2010 Feb; 48(2):568-74. PubMed ID: 19940054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
    Casapao AM; Davis SL; McRoberts JP; Lagnf AM; Patel S; Kullar R; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4636-41. PubMed ID: 24890596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of SCCmec type V and agr type I among heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in north India.
    Singh A; Prasad KN; Rahman M; Rai RP; Singh SK; Srivastava JK
    J Glob Antimicrob Resist; 2017 Mar; 8():110-114. PubMed ID: 28109847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome.
    Kim T; Kim ES; Park SY; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Chong YP; Kim YS
    Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1473-1481. PubMed ID: 28337607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.